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ABSTRACT 
Objective:  HIV infection is a global pandemic with approximately 37 million adults infected 
worldwide.
1
 Numerous abnormalities predisposing to a hypercoagulable state have been 
described in patients with HIV infection and include deficiencies of antithrombotic proteins 
and the presence of procoagulants. The abnormalities have been described to correlate with 
the degree of HIV associated immunosuppression as well as with the presence of concomitant 
infections and / or neoplastic disorders.  The conclusion of several studies
2-3
 has been that 
although evidence pointed towards a relationship between HIV infection and venous 
thrombotic disease, more studies were indicated to further elucidate this link. The majority of 
studies reporting on the documented prothrombotic abnormalities in HIV infection were 
conducted in first world cohorts. 
The objective of the study was to determine the prevalence of underlying HIV infection in 
patients presenting with acute deep vein thrombosis (DVT) without the presence of 
traditional risk factors for DVT. This prevalence was compared to the HIV prevalence in a 
sex, age and race matched control group without symptomatic DVT. In addition, the possible 
pathophysiological mechanisms for DVT development in this cohort are detailed.   
Methods: Consecutive adult patients presenting to the Charlotte Maxeke hospital casualty 
with lower limb acute deep vein thrombosis (DVT) were invited to participate in the study. 
Voluntary HIV testing of the participants were performed after counselling and consent with 
appropriate referral for further management if HIV result was positive. A record review was 
performed and information regarding the presence of commonly encountered traditional risk 
factors for the development of DVTs. The control group was an age, sex and race matched 
cohort to establish the prevalence of HIV infection in a matched population without 
symptomatic DVTs. A review of the literature to identify the possible underlying causative 
factors linking HIV and DVT was conducted. 
Results: The HIV prevalence in the DVT group who consented to HIV testing and who had 
no traditional risk factor for DVT development (22 patients) was 81% (95% CI 0.67 - 0.96). 
The HIV prevalence in a matched control group without symptomatic DVTs was found to be 
4% (95% CI 0.039 – 0.041). All the DVT patients who consented to HIV testing were active, 
community integrated members of the society. The average CD4 cell count of the HIV  
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positive patients with acute DVTs was 247 /mm
3
. Two of the HIV positive patients with 
DVTs were on ART (anti-retroviral therapy) and 4 were also diagnosed with pulmonary 
tuberculosis. Traditional DVT risk factors identified in the HIV infected DVT cohort other 
than tuberculosis were immobilisation and carcinoma.   
Conclusion: A prothrombotic state is present in HIV infected individuals giving rise to an 
increased prevalence of thrombotic complications with potentially fatal consequences. The 
risk of DVTs in the general population is 0.10 % a year
2
 but the current and other studies 
indicate that the prevalence in HIV positive patients is significantly increased. From this 
thesis it is clear that there is no available evidence evaluating thromboprophylaxis 
specifically in HIV-infected individuals. The available thrombosis treatment guidelines lack 
recommendations in this growing sub-population. Important treatment decisions are therefore 
left to medical attendants without clear guidelines. HIV infection in the ARV era is a chronic 
disease with a clearly prothrombotic tendency. Future studies and guidelines should further 
define the thrombotic risk in the HIV infected population and direct treatment and 
prophylaxis. 
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1. Introduction 
1.1 Background 
HIV infection is a global pandemic with approximately 37 million adults infected 
worldwide and sub-Saharan Africa is severely affected. South Africa has never 
experienced an epidemic of the magnitude of HIV/AIDS with an estimated 600 
new infections occurring per day.
1
 
 
A number of studies have been conducted to 
estimate the prevalence of HIV infection in the South African population. The 
most recent study, the South African National HIV Prevalence, HIV Incidence, 
Behaviour and Communication Survey was conducted in 2005 and provides 
estimates of the first nationally representative HIV prevalence in South Africa. 
The study, which involved more than 15 000 South Africans, showed an overall 
HIV prevalence of 10% which means that 4.8 million people older than 2 years 
were living with HIV/Aids in South African homes in 2005. These figures 
indicate that South Africa continues to have the largest documented number of 
people infected with HIV in the world. This epidemic continues to pose 
challenges to health care providers and policy makers. 
  
Diverse clinicopathological processes have been linked to infection with HIV. 
These abnormalities have mainly been documented in First world Caucasian 
populations. HIV is associated with an increased risk of opportunistic infections, 
various malignancies as well as arterial and venous thrombotic disease. The 
literature contains various reports of thrombotic episodes in HIV infected 
individuals. Numerous abnormalities predisposing to a hypercoagulable state have 
been described in patients with HIV infection (Table 1):
2-3
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Table 1: Documented abnormalities in HIV predisposing to    
hypercoagulability:
2-3
 
Deficiencies of 
antithrombotic 
proteins 
 Protein S 
 Protein C  
 Antithrombin 
 Heparin-cofactor II 
Presence of 
procoagulants 
 Antiphospholipid antibodies  
 Increased coagulation factor VIII  
Miscellaneous  Elevated von Willebrand factor 
 Cellular microparticles 
 Endothelial cell activation 
 Concurrent malignancies and 
opportunistic infections 
 
The first reported cases of HIV infection in South Africa occurred in 1982 with 2 
distinct HIV epidemic patterns. Initially the infection was prevalent in White 
homosexual males. Their infections were caused by HIV-1 clade B. By 1989, the 
second epidemic was recognised primarily in the Black heterosexual population 
and the HIV-1 clade involved was mainly C.
4
 The identification of different HIV 
groups relates to HIV viral genetic and molecular heterogenicity with distinct 
groups of HIV-1 viruses having been identified. One of these subgroups, group M 
(Major) is responsible for the majority of infections worldwide. Within group M, 
9 subgroups or clades designated A through to K have been identified. Currently 
clade B constitutes the majority of infections in the first world with the African 
and Indian epidemic consisting largely of infections by clade C. Clade B and C 
are represented in the Asian epidemic.
5
 
 
Subtype diversity in co-receptor usage, disease progression and transmissibility 
has been documented. Increasing evidence suggests that all clades of HIV 
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probably display similar sensitivity to antiviral drugs. However, viruses from 
some subtypes and/or geographical regions may have a greater propensity to 
develop drug induced resistance. In addition, differences in regard to replication 
capacity or fitness may exist among various HIV subtypes and these differences 
may become magnified under conditions of drug resistance. Immunological 
pressures may also play an important role in the evolution of viral subtypes that 
impact on ultimate drug resistance profiles.
6
 
 
Racial differences in host response to HIV infection of the same clade also exist. 
Chronic renal disease (CRD) and end-stage renal disease (ESRD) are important 
co-morbid conditions that are prevalent in HIV-infected individuals. An 
American based study
7
 assessed the incidence and progression of HIV-related 
CRD in an  African-American cohort comparing the results with a white cohort. 
Disparities were documented in HIV-related ESRD between the racial groups. In 
HIV-infected individuals, the risk of ESRD was approximately 50-fold higher in 
African Americans than in Whites. Although the racial differences in the natural 
history of CRD that underlie this discrepancy have not been well characterised, 
the results of this study suggest a more aggressive natural disease history in 
African-Americans. 
 
 The underlying pathogenesis of the abnormalities predisposing to a 
hypercoagulable state in individuals with HIV infection is probably multifactorial 
and may include reduced synthesis of proteins, presence of inhibitory antibodies, 
abnormal distribution between free and bound moieties, losses of protein due to 
renal abnormalities and endothelial damage.
3
  
 
   The factors contributing to a hypercoagulable state in HIV are discussed in  
  the section that follows. Traditional DVT risk factors are also reviewed as  
  they will add to the thrombotic risk in HIV infected individuals. 
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1.2 Protein S 
1.2.1  Physiologic action  
  Protein S, a vitamin K dependent protein produced in the liver, endothelial cells 
and megakaryocytes, acts in vivo as a natural non-enzymatic co-factor  for 
activated protein C (APC) in the degradation of phospholipid bound coagulation 
factors Va (FVa) and VIIIa (FVIIIa).
8-9
  
 
Proteolytic inactivation of FVa by the protein S / C complex occurs at the amino 
acid arginine at position 306 and 506 (Arg
306 
and Arg
506
). Initially the majority of 
the FVa molecules are cleaved at Arg
506
 yielding partially active intermediates 
followed by complete inactivation through cleavage at Arg
306
.  Protein S enhances 
APC-catalysed cleavage at Arg
306 
approximately 20 times and further also 
counteracts factor Xa (FXa) protection of FV proteolysis at Arg
506  
by APC.
9
 
 
Protein S also enhances the inactivation of coagulation factor VIIIa (FVIIIa) by 
APC, especially in the absence of coagulation factor IXa (FIXa). Proteolytic 
inactivation by APC of FVIIIa at Arg
336 
and more specifically Arg
562
 is increased 
3 fold in the presence of protein S. If FIXa is however present, protein S is only a 
weak enhancer of FVIIIa inactivation, unless coagulation factor V (FV) is present. 
Protein S and FV therefore acts synergistically in APC proteolysis of FVIIIa 
although the exact underlying molecular pathways remain unclear.
9
 
 
Protein S also forms a 1:1 stoichemetric complex with one of the regulatory 
proteins of complement, the C4-binding protein (C4-BP). Initially it was thought 
that the bound form of protein S is inactive and unavailable to act as a co-factor 
for APC.
10
  Recent studies have however demonstrated that protein S bound to 
C4-BP (PS-C4-BP) is still able to augment the proteolysis of FVa at Arg
306 
more 
than 10 fold.  The rate of cleavage of FVa by APC at Arg
506
 is inhibited by PS-
C4-BP 4 fold. The net effect of the PS-C4-BP complex is an overall decreased 
augmentation of APC with resultant reduced inactivation of FVa. The PS-C4-BP 
also enhances APC inactivation of FVIIIa. In contrast to free protein S, it does not 
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synergise with FVa. These observations suggest that rather than inhibiting the 
activity of protein S, C4-BP may alter the function of protein S.
9
 
 
In addition to its anticoagulant activity through its APC co-factor role, protein S 
also has APC independent anticoagulant action by inhibiting thrombin formation 
via the tissue factor pathway inhibitor (TFPI) pathway. TFPI down regulates the 
activity of tissue factor (TF) by forming a bimolecular complex with FXa and 
subsequently an inactive quaternary complex consisting of coagulation factors 
VIIa, Xa, TF and TFPI. Protein S accelerates the formation of the inactive FXa / 
TFPI complex 10 fold. Protein S is also involved in the inflammatory process and 
cellular apoptosis.
9
 
 
1.2.2  Protein S deficiency 
Protein S levels vary considerably with age, sex, lipid levels, hormonal and 
smoking status. Protein S levels are for example lower in pregnancy and in 
women on the oral contraceptive pill, especially preparations containing 
desogestral and cyproterone acetate. Other acquired causes of decreased protein S 
levels include disseminated intravascular coagulation (DIC), liver synthetic 
dysfunction, certain autoimmune diseases, infections such as HIV and warfarin 
therapy.
9
  
 
In addition to the acquired causes of protein S deficiency, congenital deficiencies 
do occur but are rare (a prevalence of less than 0.5% of the population) with 
various usually autosomal dominant genetic mutations being responsible. In 
addition, genetic polymorphisms in the protein S and C4-BP genes contribute to 
variations in  total and free protein S levels respectively and further contribute to 
inter-individual variability in protein S levels.
9
 
 
Congenital protein S deficiency has been firmly established as a risk factor for 
venous thrombo-embolism (VTE) with a 5 – 10 fold increased risk in family 
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studies. Acquired protein S deficiency has also been demonstrated to be a risk in 
the development of VTE often acting in conjunction with other prothrombotic 
factors.
9
  
 
1.2.3 Protein S deficiency in HIV infection 
 The prevalence of protein S deficiency in HIV infected patients has been  
 reported in various studies to be between 20 and 80%.
8
 The underlying 
 pathogenesis and consequences of protein S deficiency in HIV infection have 
 been investigated by various studies as detailed in the section to follow. 
 
 HIV associated protein S deficiency involves not only a reduction in the free 
fraction but also total protein S levels.
2
 Reduction in the free protein S fraction 
may relate to increased levels of C4b-BP, the level of which increases during 
infection and / or inflammation.
11
 
 
The reduction in total and free protein S levels in HIV might be related to T-cell 
apoptosis resulting in the formation of microparticles which bind and eventually 
remove protein S from the circulation.
10
 
 
 An autoimmune basis for the acquired protein S deficiency has been  postulated 
in various studies. Lafeuillade et al.
8
 evaluated the role of anti-protein S antibodies 
in protein S deficiency in 55 HIV positive patients. The  authors demonstrated the 
presence of anti-protein S antibodies to be linked to the reduced protein S levels 
(p=0.01). The conclusion of this and other studies
12-13
 are that protein S antibodies 
occur frequently in patients who are infected with HIV.  
 
Erbe et al.
14
 demonstrated a statistically significant (p=0.011) association between 
decreased protein S levels in an HIV positive cohort consisting of 49 consecutive 
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patients. These patients had either opportunistic infections (such as Cryptococcal 
meningitis and tuberculosis) or concomitant malignancies (such as lymphoma). 
Protein S levels responded to treatment of the secondary infections and / or 
malignancies. A positive correlation between decreased protein S levels and 
increased CRP and decreasing viral load was also established.  
 
Another postulated mechanism of protein S deficiency in HIV is decreased  
synthesis as described by Hooper et al.
15
  Tumour necrosis factor-alpha (TNF) 
levels are increased in HIV infection and have also been reported to induce a 
procoagulant state on the surface of endothelial cells.  In this study the authors 
demonstrated down regulation of protein S synthesis in a human endothelial cell 
line secondary to exposure to recombinant TNF-alpha (rTNF-alpha). 
 
1.3 Protein C 
1.3.1 Physiologic action 
Protein C is an endogenous vitamin K dependent serine protease which exhibits 
antithrombotic properties. Protein C is converted to activated protein C (APC) 
when thrombin complexes with thrombomodulin, an endothelial surface 
glycoprotein.  The activation of protein C is facilitated by endothelial protein C 
receptor (EPCR) present mainly on blood vessel endothelium. The concentration 
of circulating APC, when endothelial function is normal, is proportional to the 
amount of thrombin and protein C present. In severe sepsis, the host response 
results in generalised systemic dysfunction of the endothelium with suboptimal 
activation of protein C. This was the impetus  for the development of recombinant 
human activated protein C (drotrecogin), as a treatment option in patients with 
severe sepsis.
16
 
 
Protein C exerts its anticoagulant effect through inhibition of activated  
coagulation factors V and VIII, a function augmented by protein S, with resultant 
decreased thrombin generation. The antithrombotic function of protein C also 
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further involves enhanced fibrinolysis via its inhibition of plasminogen activator 
inhibitor 1 (PAI-1).
16
 
 
In addition, APC exhibits multiple other biological activities and is an important 
modulator of severe infection. Inhibition of thrombin generation is indirectly 
anti-inflammatory. Direct anti-inflammatory and anti-apoptotic actions of protein 
C involve interaction with its receptor, endothelial protein C receptor (EPCR). 
EPCR is present on endothelium, certain white blood cells (neutrophils, 
monocytes and eosinophils) and respiratory epithelium. The direct anti-
inflammatory actions involve decreasing the interaction between leucocytes and 
the endothelium and reducing chemotaxis of leukocytes in response to 
chemokines.
16
 
 
1.3.2 Protein C Deficiency 
 Protein C deficiency is a well accepted risk factor for venous thrombo-embolic 
disease and can either be congenital or acquired.  
 
Congenital protein C deficiency is a rare and heterogeneous condition with a 
prevalence of 0.2 to 0.4% in healthy blood donors and approximately 1.5 % in 
first time patients with thrombo-embolic disease. Thrombo-embolic disease in 
patients with congenital protein C deficiency tends to occur at a younger age and 
often in combination with other acquired risk factors such as pregnancy. 
Congenital protein C deficiency can be divided into type I (concordant reduction 
in protein C activity and antigen levels) and type II (reduced protein C activity 
but normal antigenic levels). A total of 160 different mutations have been 
identified with both clinically recessive as well as dominant forms. There is no 
ethnic distribution of congenital protein C deficiency. The increased tendency 
towards thrombotic disease is present even in the heterozygous form of the 
disease with a 8 – 10 fold increased risk. The rare finding of homozygous protein 
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C deficiency is frequently associated with purpura fulminans, a severe form of 
DIC presenting in the neonatal period.
17
 
 
Acquired protein C deficiency is usually secondary to liver synthetic 
dysfunction, vitamin K deficiency, warfarin therapy or increased consumption 
related to thrombosis or DIC. HIV infection is now also a well established 
secondary cause of protein C deficiency.
14
 
 
1.3.3 Protein C deficiency in HIV infection 
Protein C deficiency has been documented to be present in up to 14% of HIV 
infected individuals
14
 but has not been as clearly delineated as that of protein S 
deficiency.
18
 The underlying cause, as in HIV related protein S deficiency, is 
probably multi-factorial. The protein C deficiency in HIV comprises both 
decreased levels of total (antigenic) as well as active (functional) protein C.
3
 
 
A trend towards normalisation of protein C activity has been demonstrated in 
HIV positive patients when opportunistic infections have been treated 
successfully and anti-retroviral therapy has been initiated.
14
 The association 
between superimposed infections in HIV positive patients and reduced APC 
activity may be related to the development of anti-phospholipid antibodies which 
interfere with the interaction between protein C and its target receptors.
2
 In 
addition, protein C consumption is probably increased during acute infection 
relating to its anti-inflammatory function.
11
  It has therefore been hypothesised 
that the decline in protein C levels in HIV may be secondary to a low-grade 
consumptive coagulopathy rather than decreased synthesis or altered 
metabolism.
19
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1.4 Antithrombin 
1.4.1 Physiological action 
Antithrombin (AT), a hepatocyte synthesised serine protease, is the most 
important physiological inhibitor of activated coagulation factors II, IX, X, XI 
and XII. Inhibition of the activated coagulation factors occurs by the formation of 
an equimolar complex between AT and the activated coagulation factor, a process 
accelerated by heparin.
3
 
 
1.4.2 Antithrombin deficiency 
Homozygous congenital antithrombin deficiency is not compatible with life. 
Heterozygous deficiencies are heterogeneous with two distinct subtypes 
described: Type I and II. No ethnic data on the distribution of antithrombin 
deficiency is available.
17
 
 
Type I congenital deficiency is associated with both a reduction in functional and 
immunological antithrombin levels with more than 80 point mutations and 12 
major gene deletions underlying these deficiencies. The prevalence of type I 
antithrombin deficiency is estimated to be 0.2% of the general healthy population 
and 1% of patients presenting with first time VTE. Type I deficiency is clearly 
related to increased risk of VTE occurring at a median age of 26 years of age.
17
 
 
Type II congenital deficiency of antithrombin is associated with reduced 
functional but normal immunogenic levels of antithrombin. Various mutations 
have been described affecting different functional domains of antithrombin 
including the heparin binding site domain. The prevalence of type II antithrombin 
deficiency in healthy blood donors has been reported to be 1.45 per thousand. The 
risk of VTE in type II deficiency is lower than that in type I deficiency.
17
 
 
 11 
 
Acquired causes of antithrombin deficiency include consumptive coagulopathy 
(DIC) with increased utilisation, nephrotic syndrome with increased renal loss, 
protein-losing-enteropathies with increased gastro-intestinal loss and liver disease 
with decreased synthesis. Increased cleavage by proteolytic enzymes may also 
contribute to acquired antithrombin deficiency as can heparin therapy.
2-3, 19
  
 
1.4.3 Antithrombin deficiency in HIV infection 
Acquired antithrombin deficiency in HIV infection is probably caused by 
multiple mechanisms including malnutrition, decreased liver synthesis and 
increased renal loss secondary to nephrotic syndrome with the antithrombin levels 
being inversely proportional to the degree of proteinuria. Inactivation by 
proteolytic enzymes has also been postulated to be a contributing factor. The 
exact contribution of these various factors in lowering antithrombin levels in HIV 
infection is unknown.
2-3
 HIV associated malignancies may also play an 
aetiological role in HIV antithrombin deficiency.
18
 
 
1.5 Heparin cofactor II 
1.5.1 Physiological role 
Heparin cofactor II (HC II) is synthesised in the liver and is a natural glycoprotein 
thrombin inhibitor with a structure very similar to antithrombin. HC II inactivates 
both free and clot based thrombin but has no inhibitory effect on any of the 
coagulation proteins other than thrombin.
20
 The anticoagulant activity of HC II is 
enhanced by glycosamine glycans (GAGs) such as dermatan and heparin 
sulphates (DS & HS) which are naturally present in vessel walls and synthesised 
by cells such as fibroblasts.
2, 21
 Results of various studies support the hypothesis 
that HCII interacts with DS & HS in the vessel wall after injury of the 
endothelium and that this interaction contributes to the regulation of thrombus 
formation in vivo.
21
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1.5.2 Heparin cofactor II deficiency 
Congenital deficiency of HC II has been reported to be associated with recurrent 
arterial thromboses although the aetiological link between HC II deficiency and 
VTE remains controversial.
19
 Although experimental work has demonstrated that 
HC II can contribute as much as 20 – 30% to thrombin inhibition during thrombus 
formation, neither mice nor humans deficient in HC II exhibit hypercoagulable 
states during normal conditions.
20-21
  Recent data suggest that the primary 
physiological function of HCII is to inhibit thrombin’s non-haemostatic roles e.g. 
development of atherosclerosis with HC II protecting against arterial 
atherosclerosis and preventing restenosis post thrombolysis, balloon-angioplasty 
or stenting procedures. Elevated levels of HCII has therefore been shown to 
protect against atherosclerosis and restenosis.
20
 In contrast patients with low 
plasma concentrations of HCII do not appear to be at increased risk for venous 
thrombosis, but they may be predisposed to development of atherosclerosis
 
and 
neo-intima formation following angioplasty and stent placement. 
 
1.5.3 Heparin cofactor II deficiency in HIV infection 
A higher prevalence of acquired HC II deficiency has been demonstrated in HIV 
infected patients with CD4 counts below 200 x 10
6
 per liter compared with HIV 
patients with higher CD4 counts and HIV uninfected people. This suggests a 
possible association between HC II deficiency and immunodeficiency.
19, 22
 The 
postulated mechanisms of HC II deficiency in HIV infection include decreased 
synthesis, proteolysis, neutralising antibodies and redistribution from the 
intravascular to the extravascular space secondary to endothelial cell dysfunction.   
2, 19
  No study has, however, clearly demonstrated a link between HC II deficiency 
in HIV and the documented prothrombotic state in HIV.
18
  
 
1.6 Antiphospholipid antibodies 
1.6.1 Role in disease  
Antiphospholipid antibodies (aPLAs) including lupus anticoagulants (LA) and 
anticardiolipin antibodies (aCLAs) are a family of acquired auto-antibodies 
directed mainly against negatively charged phospholipids bound to phospholipid-
 13 
 
binding proteins. They can occur in a background of another disease process such 
as autoimmune diseases e.g. systemic lupus erythematosis (SLE), infections e.g. 
HIV, drug exposure, neoplasms or haematologic diseases (then referred to as 
secondary aPLAs). aPLAs can also occur alone with no background disease 
process, then referred to as primary aPLAs. The principle clinical manifestations 
of aPLAs include venous and arterial thromboses, recurrent miscarriages and 
thrombocytopenia with LA being a stronger predictor of thromboses than aCLAs. 
The underlying pathophysiological mechanism of thrombosis is thought to 
involve interference with endothelial cell function, including decreased 
prostaglandin production and interference with endothelial cell mediated protein 
C activation via thrombomodulin.
3
 Laboratory detection of these autoantibodies is 
based on both functional clot and ELISA based tests.
23-24
 Functional assays 
involve demonstration of prolongation of phospholipid based coagulation assays 
such as dilute Russell viper venom time (DRVVT) due to interference by 
aPLAs.
3, 23-24
  
 
The combination of antibodies detected in the laboratory and clinical 
manifestations may then fulfill the criteria for the diagnosis of antiphospholipid 
syndrome.
25
  
 
1.6.2 Disease processes in HIV infection 
The results of antiphospholipid antibody (aPLA) testing in HIV patients have 
yielded conflicting results as far as the prevalence and clinical significance of 
these antibodies are concerned. Some studies have demonstrated a high 
prevalence of aPLAs in individuals with HIV infection with aCLAs detected in 
up to 90% and LA in 70% of patients.
3
 Lijfering et al.
11
 however did not observe 
the same prevalence of LA and aCLAs in their study in which they measured 
markers of coagulation during the course of HIV infection in 109 consecutive 
HIV positive patients. They attributed this lower prevalence in their study to 
previous studies not following the same strict guidelines to diagnose lupus 
anticoagulant and anticardiolipin positivity. Other studies failed to detect these 
autoantibodies in any of the HIV positive patients in their cohorts.
23- 24
 Various 
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studies have found a relationship between the prevalence of aPLAs and 
progression of HIV infection with the highest prevalence being detected during 
the final stages of the infection i.e. AIDS.
24
  Klein et al.
2
 in their review of the 
relationship between chronic HIV infection and venous thrombotic disease 
concluded that the presence of aPLAs in HIV-infected patients was not related to 
the stage of the infection as determined by the CD4 cell count and / or the HIV 
viral load. 
  
The origin of aPLAs in HIV infection has been postulated to be either secondary 
to specific or non-specific stimuli. The specific antibody production being related 
to the release of phospholipid antigens from the cell membranes of necrosing host 
cells with aPLAs playing a scavenging role mopping up debris of self damage. 
Opportunistic infections such as CMV can also release phospholipid antigens 
initiating a similar antibody production process stimulated by a specific antigen.
18
 
Non-specific antibody production relates to the immune dysregulation in HIV 
infection secondary to regulatory CD4 positive T-helper cells being targeted and 
depleted by HIV resulting in a non-specific polyclonal gammopathy.
3, 23-24
  
 
Studies attempting to establish the clinical significance of aPLAs in HIV 
infection have also drawn different conclusions. Although aPLAs have been 
commonly detected in patients with HIV infection, the clinical manifestations of 
the antiphospholipid syndrome are uncommon in patients with HIV infection but 
do occur. Only 5 cases of full blown antiphospholipid syndrome in HIV infection 
had been described in the English literature by 2004. Thromboses, arterial and 
venous, do however occur more frequently in HIV infected patients with aPLAs 
compared with other viral infections with associated aPLAs. This fact suggests 
more major disturbances of the immune system and the presence of other co-
morbidities i.e. malignancies and opportunistic infections such as Pneumocystis 
jiroveci and Cytomegalo virus (CMV) during the course of HIV infection.
3, 23-24, 
26
 Other studies, such as that by Palomo et al.
27
 for example, have failed to 
demonstrate an association between the presence of aPLAs and thrombosis in 
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HIV infection. The theoretically increased risk of thrombosis in the face of 
aPLAs can in part at least be explained by inhibition of APC by aCLAs.
2
 
 
In SLE an association between the level of aPLAs and the degree of 
thrombocytopenia has been demonstrated but no such a relationship has been 
found in HIV infections.
3
 The absence of such a relationship is probably due to 
the multifactorial pathogenesis of thrombocytopenia in HIV infection.   
 
1.7 Coagulation Factor VIII 
1.7.1 Physiological role 
Coagulation factor VIII (FVIII) is synthesised in the liver and circulates in plasma 
in a non-covalent complex with von Willebrand factor (vWF) which protects it 
against degradation in the circulation, thus prolonging its half life. FVIII is 
activated by thrombin or factor X (FX) through cleavage at arginyl residues 
which results in a heterodimeric molecule consisting of 3 domains non-covalently 
linked through calcium ions. FVIII, in combination with coagulation factor IX 
(FIX), activates FX which in turn, together with factor V (FV), has 
prothrombinase activity. The main inhibitor of activated FVIII is protein C, a 
naturally occurring proteolytic enzyme. Deficiency of FVIII results in the sex-
linked bleeding disorder, haemophilia A. Elevated FVIII is generally defined as a 
level greater than 150% of the level in normal reference plasma.
5, 28
 
 
1.7.2 Elevated factor VIII levels 
Increased levels of various clotting factors have been considered in the quest to 
identify risk factors which increase the incidence of thrombosis. Elevation of 
coagulation FVIII has been consistently found to be a risk factor in the 
development of both primary and recurrent VTE. The increase in risk is, 
however, not linear with the increase in thrombosis incidence only being present 
when FVIII levels exceed a level of approximately 230 – 250%. The prevalence 
of elevated basal FVIII level in the general HIV negative population has been 
reported to be 10%.
11
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 Although elevation of FVIII can be an acute phase reaction, basal FVIII levels 
are genetically determined and seem to be linked to the underlying blood group 
with non-O individuals having higher basal FVIII levels. FVIII levels may be 
useful in determining the duration of anticoagulation therapy post thrombosis but 
this still has to be researched further.
28-29
 Cosmi et al.
28
 demonstrated a risk of 
recurrence that was more than 5-fold higher when basal FVIII levels were above 
the 90
th
 percentile and 3-fold higher with basal FVIII levels above the 75
th
 
percentile of normal. In addition, Goldenberg et al.
30
  demonstrated that the 
combination of elevated FVIII and D-dimer levels was predictive of poor 
outcomes including lack of complete recanulisation, recurrence of thrombosis and 
development of the post-phlebitic syndrome in children.  
 
1.7.3 Elevated factor VIII levels in HIV infection  
Elevated FVIII levels have been demonstrated to be present in up to 41% of HIV 
positive individuals, with the median FVIII level being higher in patients with 
AIDS defining illnesses and CD4 counts below 200 x 10
6
 per liter compared with 
the earlier stages of HIV infection. A stepwise increase in FVIII levels has been 
demonstrated in a study by Levine et al.
24
 This study, focusing on female patients 
without an underlying cause for elevation of acute phase reactants, demonstrated 
a median FVIII level of 116% in HIV negative women, 149% in those with 
asymptomatic HIV infection, 196% in those with immunologic AIDS and 211% 
in patients with clinical AIDS. The difference in FVIII levels between the 
different groups in this study was statistically significant with p < 0.0001.
24
  In 
addition, elevated FVIII levels were associated with increased fibrinogen and 
decreased protein S concentrations, both factors in themselves being 
procoagulant. The rise in FVIII levels with advancement of the HIV infection 
may be due to the HIV infection itself, since the same cytokines that activate the 
coagulation system have been described to be operational in the setting of 
advancing HIV.
11
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1.8 Miscellaneous factors 
1.8.1 Von Willebrand factor 
Von Willebrand factor (VWF), a multimeric glycoprotein, plays a crucial role in 
platelet adhesion and aggregation, known to be the main initial steps in 
haemostasis. Each von Willebrand factor (vWF) molecule has binding sites for 
platelet glycoproteins, coagulation FVIII, for which it serves as a carrier 
molecule, and collagen. VWF is almost exclusively produced by endothelial cells 
and, as such, serves as a useful marker of endothelial cell damage and 
dysfunction. Considering the pivotal role of vWF in thrombogenesis, therapies 
that specifically inhibit vWF have been considered as potential anticoagulant 
agents.
31-32
 
  
Release of excessive amounts of vWF has been linked to the development of 
thrombotic thrombocytopenic purpura (TTP), a microangiopathy occurring with a 
significantly increased incidence in HIV infected patients. Although the numbers 
reported in the literature are small, only 44% of HIV related TTP patients have 
been demonstrated to have a significant deficiency of ADAMTS 13, the 
metaloprotease responsible for cleaving large monomers of vWF. In addition, 
only 42% of these patients have a demonstrable ADAMTS 13 inhibitor. These 
findings are in contrast to those in idiopathic TTP in which most patients have a 
severe deficiency of ADAMTS 13. Of further interest is the fact that none of the 
patients with CD4 counts less than 100 cells per liter had a severe deficiency of 
ADAMTS 13.
33
 
 
Administration of DDAVP to healthy volunteers has been shown to lead to 
release of vWF with transient decreases in ADAMTS 13 activity. As far as the 
pathogenesis of TTP in HIV is therefore concerned, it is hypothesised that 
ongoing release of vWF from endothelial cells leads to an ongoing clearance and 
relative deficiency of ADAMTS 13. Reports have also demonstrated D-dimer 
levels to be often elevated in patients with HIV related TTP
34
 and in vitro studies 
have shown that the presence of thrombin leads to lower ADAMTS 13 activity.
33
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It is therefore possible that endothelial activation and / or damage as is discussed 
in 1.8.2 can lead to the release of excessive amounts of vWF, localised thrombin 
generation and consumption of ADAMTS 13 expressed phenotypically as TTP.
33
 
It also seems plausible that elevated vWF with the associated elevation in FVIII 
contributes to the HIV hypercoagulable state. 
 
1.8.2 Endothelial cell activation 
A link between infection and thrombosis via endothelial cell activation has been 
postulated. Pro-inflammatory cytokines probably play an important role in this 
process.
11, 35
 Numerous studies have concluded that the thrombotic state in HIV 
infection is caused by endothelial injury and / or dysfunction. 
3, 36-37
   
 
As previously noted vWF levels are increased in HIV infection with the increase 
correlating with the degree of immunosuppression as measured by CD4 cell 
counts. As vWF is an endothelial cell product which is released as these cells are 
injured, the increased vWF concentration in the circulation serves as a surrogate 
marker of underlying endothelial cell damage. 
 
Evidence of direct infection of the endothelial cells by HIV has been sought 
utilising immunohistochemical stains and fluorescence in situ hybridisation 
(FISH).
3
  Although the presence of one of the HIV capsular antigens, p24, has 
been demonstrated in endothelial cells
38
 it remains uncertain whether HIV 
directly infects and damages endothelial cells. In vitro infection of human 
umbilical vein endothelial cells (HUVECs) with HIV has been demonstrated.
39
 
These infected endothelial cells up-regulated the production of interleukin-6, 
interleukin-1β, and granulocyte colony-stimulating factor. These cytokines in turn 
then stimulate HIV replication. To date studies have, however, been unable to 
conclusively prove that HIV actively infects human endothelial cells in vivo.   
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HIV proteins can damage the endothelium by various mechanisms. The HIV viral 
genome encodes for approximately 15 mature HIV proteins which may interact 
with host targets. HIV is a double-stranded RNA retrovirus belonging to the 
lentivirus (“slow virus”) group. The viral genome, packaged in a nucleocapsid 
core, is surrounded by a matrix and a glycoprotein-rich envelope. The HIV 
genome contains 9 main genes: gag, pol, env, tat, rev, vpu, vpr, vif and nef. 
Proteolytic cleavage of the gag-pol precursor protein yields the major structural 
components of the viral core (i.e. matrix p17, capsid p24, nucleocapsid p9 and p6, 
reverse transcriptase, protease, and integrase). Proteolytic cleavage of env 
produces the important envelope glycoproteins gp120 and gp41. The remaining 
genes encode for the regulatory proteins tat and rev and the accessory proteins 
vpu, vpr, vif, and nef. Table 2 provides a summary of the mature HIV proteins, 
their roles in the viral replication-cycle and known effects on endothelial cell 
homeostasis.
40
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Table 2: Effects of HIV-1 proteins on viral function and endothelial cell  
biology:
40
 
Protein Viral Function Endothelial Cell Effects 
Vpr Block cell division ↑ apoptosis 
Tat Transcriptional transactivator of RNA ↑ apoptosis 
↓ relaxation 
↑ CAMs 
↑ MCP-1 
↑ adhesion, 
regulate cytoskeleton 
↑ permeability 
↑ MMP 
↑chemotaxis 
↑ proliferation 
↑ angiogenesis 
↑ ROS 
Vpu Virus release; ↓CD4 ↑ CAMs 
gp120 Receptor binding ↑ apoptosis 
↑ CAMs 
↑ adhesion 
regulate cytoskeleton 
↑ permeability 
↑ vasoconstrictors 
↑ ROS 
Nef ↓ CD4 and Class I MHC; ↑ viral infectivity ↑ apoptosis 
↑: increase; ↓: decrease; CAM: cell adhesion molecule; MCP: monocyte 
chemotactic protein-1; MMP: matrix metalloproteinase; ROS: reactive oxygen 
species; MHC: major histocompatibility complex. 
 
Torriani et al.
41
 assessed endothelial cell function in ARV naïve HIV infected 
patients by measuring flow-mediated dilation (FMD) of the brachial artery in a 
cohort of 82 patients. The results of this study demonstrated a significant 
improvement in FMD after initiation of ARVs in spite of blood lipid profiles 
worsening on ARVs. This study focussed on the arterial side of the vascular tree 
and concluded that patients with HIV-infection who met criteria for starting ART 
had impaired endothelial function. The cause for this dysfunction was postulated 
to relate either directly or indirectly to HIV infection with infected patients 
demonstrating increased expression of both vascular cell adhesion molecule-1 
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and E-selectin. There is further support of endothelial cell activation and 
dysregulation, as evidenced by increased plasminogen activator inhibitor-1 (PAI-
1) antigen and tissue-type plasminogen activator (tPA) in ARV-naïve patients. 
These patients also demonstrate positive correlation with anti-p24 antibody levels 
and disease severity.
40
 
 
The recent Strategies for Management of Antiretroviral Therapy (SMART) study 
revealed an increase in total mortality and possibly an increased risk of 
developing cardiovascular disease when ARV treatment was episodically 
discontinued.
42,
 
43
 Prolonged antiretroviral therapy has been associated with major 
metabolic and cardiovascular disorders and the authors of this study evaluated the 
efficacy of episodic antiretroviral treatment based upon CD4
+
 T-cell levels  in     
2 720 HIV positive patients. Unfortunately, interruption of antiretroviral therapy 
actually increased the incidence of major cardiovascular events in the study 
cohort. 
 
A further marker of endothelial injury is the soluble form of thrombomodulin 
(sTM). As thrombomodulin is a transmembrane protein located on the surface of 
vascular endothelium, its elevated plasma levels occur only in the presence of 
damaged endothelial cells. Studies have demonstrated elevation in sTM in HIV 
infected but ARV naive patients which normalised on ARV therapy.
44
   
 
Regardless of whether or not the HIV virus directly infects human endothelial 
cells the vascular endothelium is continually exposed to numerous viral stimuli in 
HIV infected patients. These stimuli include HIV infected cells (CD4
+
 T cells, 
monocytes, and macrophages), free circulating HIV, viral proteins released upon 
host cell lysis, actively secreted viral proteins (e.g. tat and gp120) and viral-
induced pro-inflammatory cytokines. All of these factors increase endothelial cell 
permeability and may facilitate monocyte invasion into the vessel wall. HIV-
induced cytokines may also activate the endothelium, leading to enhanced 
production of reactive oxygen species (ROS), expression of cell adhesion 
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molecules (CAMs) and the release of procoagulants such as vWF and chemo-
attractants.
40
  
 
Although altered endothelial cell homeostasis plays a more important role in the 
pathogenesis of arterial thrombosis and this dissertation is essentially concerned 
with venous thrombosis the two disorders have many features in common. 
Evidence does exist that patients with venous thrombosis may be at greater risk 
for arterial events.
 
The pathogenesis of both disorders share many factors 
including endothelial injury. While the evidence that arterial disease is a risk 
factor for
 
venous thrombosis is inconclusive, arterial disease does appear
 
to occur 
with a modestly increased frequency in patients with
 
a history of VTE.
45
 
 
18.3 Microparticles 
Microparticles are small cellular remnants circulating in plasma. They mostly 
originate from platelets, monocytes and endothelial cells. In HIV infection there 
is an increase in microparticles which originate from CD4 lymphocytes. This is as 
a direct consequence of HIV infection with resultant CD4 lymphocyte apoptosis.  
Elevated concentrations of microparticles in HIV-infected individuals have been 
demonstrated in various studies and this elevation is associated with activation of 
the coagulation cascade.
2
 The procoagulant properties of microparticles are 
believed to relate to their phospholipid rich surfaces and expression of other 
molecules, notably tissue factor and P-selectin.   
 
Tissue factor plays a major role in the initiation of blood clot formation. The 
source of the tissue factor remains somewhat controversial, since the majority of 
experimental animal models of venous thrombosis involve overt damage to blood 
vessels. Damage to blood vessels results in exposure of subendothelial tissue 
factor, but vessel wall damage does not precede the vast majority of human 
venous thromboses.
46
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There are experimental models in which blood borne tissue factor, associated 
with blood cells or microparticles derived from blood cells, probably leucocytes, 
has been shown to be involved in the genesis of thrombus. From these 
experiments it seems plausible that microparticles bearing tissue factor can serve 
as the initiator of thrombosis.
46
 
 
Under arterial and venous flow conditions, thrombus formation also appears to 
involve the adhesion molecule P-selectin. Experiments employing P-selectin 
blocking antibodies have strengthened this hypothesis. P-selectin facilitates cell-
cell interactions via PSGL-1, a major ligand for P-selectin.
46
  
 
Tissue factor and P-selectin therefore both appear to be important for thrombus 
formation. They are present on microparticles derived from monocytes.
46
 
Microparticles are elevated in HIV infection adding to the procoagulant state 
present in HIV infection.
2
 
 
1.8.4 Secondary infections 
Infection increases the risk of thrombosis. Certain infections are particularly 
associated with an increased risk including cytomegalovirus (CMV), 
Pneumocystis jiroveci and tuberculosis (TB).
3
 These infections occur frequently 
in HIV infected patients. 
 
In industrialised countries TB incidence and mortality has been consistently 
declining but globally the situation is continually worsening due to HIV co-
infection and the increase of multi-drug resistant TB strains. TB is still 
responsible for more than 1.5 million deaths every year with underdeveloped 
countries bearing the brunt. HIV/AIDS is the single biggest risk factor for TB 
infection with up to two thirds of HIV infected people also being infected with 
TB.
47
 The most resistant form of TB, XDR (extreme drug resistant) -TB is 
defined as resistance to isoniazid, rifamycin, fluoroquinolones and one of three 
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injectable second-line anti-tuberculosis agents: capreomycin, kanamycin or 
amikacin. XDR-TB cases are causing increasing alarm in South Africa where 
endemic HIV makes for a deadly combination. A report published in 2006 from a 
rural clinic in KwaZulu-Natal in South Africa, showed that MDR-TB was present 
in 221 (41%) of 542 patients with positive cultures for tuberculosis. 53 (9.7%) of 
these patients had XDR-TB. Among the XDR-TB patients with a known HIV 
status all were HIV seropositive. In that setting, XDR-TB was rapidly fatal with a 
median survival of 16 days after specimen collection. However, because the 
diagnosis of XDR-TB by drug susceptibility testing takes several weeks, these 
patients died before appropriate therapy could be administered.
48
 Although 
venous thrombo-embolism is a relatively rare complication of infection with 
tuberculosis, it may be a potentially life-threatening event. An increased 
prevalence of DVTs has been documented both prior to (as a presenting feature of 
TB infection) as well as after initiation of anti-tuberculosis therapy. 
49
  
 
Infections with Pneumocystis have been linked to the presence of  
antiphospholipid antibodies including lupus anticoagulant (LA), which is detected 
in up to 96% of HIV positive patients with concomitant Pneumocystis infection 
and this opportunistic infection has been linked to clinical thromboses.
3
 
 
CMV, a well established cause of thrombosis has been linked to peripheral 
thrombophlebitis, strokes, cerebral venous thrombosis, digital infarcts and 
pulmonary emboli. 
3, 18
  There are three mechanisms thought to be operational in 
the prothrombotic state associated with CMV infection. Firstly, CMV may lead to 
a thrombotic microangiopathy through its effect on the endothelium which is 
altered from an anti- to a prothrombotic surface. This change involves increased 
expression of tissue factor by these cells lining all blood vessels. Direct infection 
of endothelial cells with the CMV has been demonstrated in AIDS patients with 
thrombosis. A second possible mechanism involves induction of antiphospholipid 
antibodies formation. Finally it has been postulated that impaired fibrinolysis due 
to raised haemostatic parameters e.g. vWF is also operational.
3, 18
 A direct 
anatomic correlation of the physical presence of secondary infections such as 
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CMV with underlying vascular lesions has not been clearly demonstrated. A 
review of the literature does however suggest a strong association between the 
two entities. The early treatment and prevention of these opportunistic infections 
in HIV infected patients may have an impact on thrombotic episodes in these 
individuals. 
3, 19
 
 
1.8.5 Malignancies 
The association between neoplasms and thrombosis has been firmly established.   
50-52
 Venous thrombo-embolic disease (VTE) is a well known complication in 
patients with cancer. The association between occult or overt malignancy and 
thrombosis has been widely recognised since Trousseau in 1865.
53
 The overall 
risk of symptomatic VTE is increased nearly 6 to 7 fold in cancer patients with a 
20% prevalence of malignancy in elderly patients with newly diagnosed 
otherwise unprovoked VTE. VTE remains an important cause of death in cancer 
patients prior to and during the course of cancer therapy.
54
 
 
Malignancies seen with clearly increased frequency in HIV infection include 
Kaposi Sarcoma, Non-Hodgkin Lymphoma (NHL), anal and cervical 
carcinoma.
19
  
 
The pathophysiological mechanisms underlying the development of VTE in 
cancer patients are multifactorial including tissue factor (TF) expression by 
malignant cells, formation of TF-bearing microparticles and production of 
prothrombotic cytokines such as IL-1 and VEGF. Other mechanisms include 
reduction of naturally occurring coagulation inhibitors which results in activated 
protein C resistance, decreased fibrinolysis secondary to production of 
plasminogen activator inhibitor-1 (PAI-1) and increased adhesive interactions 
between tumour cells. Levels of the adhesion molecule P-selectin has been shown 
to be increased in many tumours and probably plays an important role in these 
cellular interactions. The increase in pro-inflammatory cytokines is responsible 
for increased levels of pro-inflammatory acute phase reactants such as fibrinogen, 
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vWF and FVIII.  Endothelial damage and / or activation related to surgery, 
chemotherapy, intravenous catheters or direct vascular invasion by tumour cells 
are major contributing factors. Bed rest and extrinsic compression of blood 
vessels by either tumour masses or lymph nodes may result in vascular stasis with 
thrombus formation.
54-55
 
 
The pathophysiology of cancer related thrombosis also involves other molecules 
such as cancer procoagulant which is an endopeptidase that directly activates 
coagulation factor X and causes platelet activation. This prothrombotic molecule 
is released by many tumour cells promoting thrombosis.
55
  
 
Sood S.L.
54
 recently reviewed the risk factors underlying the development of 
VTE in cancer patients and reconfirmed that the individual risk of thrombosis 
varies from patient to patient. The risk is dependent on a combination of the 
prothrombotic state induced by the specific cancer, underlying host factors and   
treatment modalities including placement of catheters, surgery and various anti-
angiogenic or chemotherapeutic agents. The thrombosis risk is increased in the 
first few months after diagnosis of a malignancy and parallels the extent of the 
malignancy with distant metastases being associated with a significantly 
increased risk of VTE. Cancer patients with history of VTE have a higher 
mortality rate compared to those without thrombosis, supporting the hypotheses 
that activation of coagulation pathways may be an important mechanism for 
tumour metastasis. 
 
VTE risk varies depending on tumour histology. Primary brain, pancreatic, 
ovarian, bone, gastric and lung cancers are the main causes of an increased risk. 
Haematological malignancies also have a high rate of VTE. Lymphoma, acute 
leukaemia and multiple myeloma patients on treatment with angiogenesis 
inhibitors have a significantly increased VTE risk. 
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Endogenous patient factors are additive to the VTE risk in cancer patients. 
Effective use of VTE thromboprophylaxis in patients with cancer is important to 
reduce morbidity and mortality, contain healthcare costs and improve quality of 
life. Although evidence based guidelines for thromboprophylaxis of hospitalised 
surgical and medical patients with cancer have been developed, recommendations 
for ambulatory cancer patients are less well established.
56
  
 
Patients receiving chemotherapy have a 2 to 6 fold higher incidence of VTE. This 
increased risk is likely to be due to a combination of endothelial injury, induction 
of activated protein C resistance and cell destruction leading to increased 
exposure of procoagulant material. Surgery and insertion of venous catheters will 
further add to the VTE risk in cancer patients.
55
  
 
Chemotherapeutic agents are also  associated with other vascular abnormalities, 
such as TTP in non-HIV patients.
52
 HIV infection itself has been associated with 
this vascular complication, the incidence of which can only be expected to be 
increased when HIV infected individuals are exposed to chemotherapeutic 
agents.
57
 The association between malignancies and thrombosis is further 
discussed in 5.6.1 of this dissertation. 
 
1.8.6  Bed rest 
Rest, specifically bed rest, is an essential part of daily living with most people 
sleeping for 6 to 9 hrs per day and also resting for shorter periods at other times. 
Obviously, when ill, people are less ambulant.
58
 
  
Research based definitions of the duration of clinically impotant bed rest differs 
between published studies, but 4 or more days is generally regarded as being 
significant.  The prothrombotic risk of bed rest contributes to the documented 
increased prevalence of DVTs in hospitalised patients with up to 20% of medical 
and 40% of surgical in-patients developing thromboses.
59
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The normally functioning human however, is physically active for substantial 
portions of each day and increased rest is associated with loss of the beneficial 
effects of physical activity and might lead to serious complications. The 
complications of bed rest include skeletal muscle atrophy, joint contractures, 
pressure ulcers, osteoporosis, metabolic consequences such as insulin resistance, 
lung atelectasis with associated infection and thrombo-embolic disease.
58
 
 
Virchow’s triad comprises the three categories of factors that contribute to 
thrombo-embolic disease: blood flow, vascular injury and coagulopathy. It is well 
known that blood flow through extremities varies directly with muscle activity 
and it therefore follows that sustained inactivity from bed rest promotes venous 
stasis. Furthermore, compression of veins from contact of limbs with the bed also 
contributes to stasis and could potentially damage the vascular endothelium. 
Hence, bed rest is an important risk factor for thrombo-embolic disease.
58
 
 
1.8.7  Pregnancy 
The association between pregnancy and VTE has been well documented in the 
literature.
46
 The pathophysiological mechanisms underlying the pregnancy 
hypercoagulable state involves elevated procoagulant factors, notably FVIII and 
fibrinogen, with a reduction in natural anticoagulants such as protein S and 
acquired activated protein C resistance (APCR). 
 
1.8.8  Post surgery period 
The risk of thrombosis after surgery varies depending on the type of surgery, 
underlying patient characteristics and duration of immobilisation.
59
 Surgery is a 
potent inducing factor of acquired hypercoagulability and prophylactic 
anticoagulation to prevent thrombosis development in the post surgical 
population has been extensively studied and included in guidelines.
56
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1.8.9  Long distance travel 
Any type of travel has the potential to increase the risk of DVT development with 
the duration being the key factor. Studies have documented that travel by air, car, 
train or bus for 4  hours or longer all double the risk for several weeks after 
travel.
59
   
 
Long distance (> 8hrs) travel by air has been more extensively studied than that 
occurring by road. Although the mechanisms underlying traveller’s thrombosis 
have not been fully elucidated, the World Health Organisation (WHO) has 
investigated the association between travel and VTE. The conclusion of this 
investigation confirmed that long distance air travel increases the risk of VTE 2-
fold. They further concluded that the aetiological factors involved in traveller’s 
thrombosis are immobility, reduced humidity, hypoxaemia due to the reduced 
ambient oxygen pressure and dehydration. VTE can also develop after long 
distance travel by car, bus or train.
60
 
 
1.9 Venous Thrombo-embolism (VTE): Prophylaxis and treatment 
Prophylactic anticoagulation with either low molecular weight heparin (LMWH) 
or unfractionated heparin (UFH) has been proven to be safe and effective in 
surgical patients and is widely used for the prevention of venous thrombo-
embolism (VTE). According to the American College of Chest Physicians 
(ACCP) guidelines
56, 61
, prophylactic anticoagulants should also be prescribed to 
medical patients who are at high risk of VTE i.e. deep vein thrombosis (DVT) 
and pulmonary embolism (PE). Scientific evidence of the effectiveness of 
anticoagulants for the prevention of VTE and reduction of mortality in this latter 
medical population group is accumulating. Studies have however documented 
universal low rates of appropriate VTE prophylaxis in at risk medical in-patients 
despite the presence of guideline recommendations and mounting evidence of its 
effectiveness.
62-63
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The reasons for the low thromboprophylaxis rates in at-risk medical patients 
compared with their surgical counterparts remain largely unclear. However, a 
number of studies have demonstrated the ability to improve thromboprophylaxis 
rates in this population via education
64-65
 and the use of special tools such as 
electronic alerts to treating physicians.
66
 
 
Recommendations of various VTE prophylaxis and treatment guidelines with 
respect to VTE prophylaxis in medical in-patients can be summarised as follows:  
 All patients should have their VTE risk assessed and addressed upon 
hospital admission, change in level of care and discharge. 
 All patients should have proper education regarding VTE risk, signs 
and symptoms of VTE and mechanical prophylaxis methods available. 
 All patients should be encouraged to ambulate as early as possible and 
as frequently as possible. 
 All non-ambulatory patients should have, at a minimum, mechanical 
prophylaxis – unless contraindicated. 
 All patients with moderate to high risk of VTE should have 
pharmacologic prophylaxis – unless contraindicated. 
  
VTE risk factors can be divided into predisposing factors (i.e. patient’s 
characteristics) and exposing factors (i.e. some medical conditions, nature of 
surgical intervention etc). Common VTE risk factors listed in guidelines on the 
subject include: 
 Prior history of VTE  
 Active cancer or myeloproliferative disorder  
  Extended immobility or estimated length of stay of 4 or more days  
 Age greater than 65 years  
 Thrombophilia – congenital or acquired  
 Congestive heart and acute respiratory failure 
 Acute infection  
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 Inflammatory bowel disease  
 Nephrotic syndrome  
 Rheumatoid / collagen vascular disorder  
 Obesity (body mass index > 30)  
 
1.10 Antiretroviral drugs 
The year 2006 marked the 25th anniversary of the initial reports of a catastrophic 
illness later termed AIDS and also the 10th anniversary of highly active 
antiretroviral therapy (ART) which revolutionised the treatment of HIV. With this 
success came the challenges of managing patients on long-term treatment for HIV 
infection, the development of drug toxicity as well as drug resistance and the 
ageing HIV-infected population. Despite treatment advances and prevention and 
education programmes, the number of HIV infected people continues to increase 
especially in the vulnerable and resource poor populations of the world.
67
 
Since the emergence of ARVs, HIV infected patients have demonstrated dramatic 
decreases in viral burden and opportunistic infections and an overall increase in 
life expectancy. There are 24 approved antiretroviral drugs targeting various viral 
proteins or critical points in the virus-host life cycle. These drugs are divided into 
5 classes according to their main mechanism of action: the nucleoside reverse 
transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), protease inhibitors (PIs), integrase inhibitors and entry inhibitors 
(EIs). NRTIs usually constitute the mainstay of antiretroviral treatment strategies. 
The current recommendations are initial combination therapy regimens consisting 
of 2 NRTIs e.g. zidovudine and stavudine or the less toxic second generation 
NRTIs tenofovir and abacavir with either 1 or 2 PIs e.g. ritonavir or 1 NNRTI e.g. 
nevirpine or efavirenz.
40
 
 
Although ARVs have undoubtedly reduced the morbidity and mortality of HIV 
infection, multiple side effects have been linked to therapy with ARVs. These 
include peripheral lipo-atrophy, steatohepatitis, lactic acidosis, anaemia, 
myopathy, pancreatitis and peripheral neuropathy. Clinical and in vitro evidence 
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also strongly suggests that long-term ARV treatment can results in endothelial 
toxicity and vascular dysfunction. Although Torriani et al.
41
 demonstrated 
improved endothelial function among treatment-naïve individuals with HIV 
started on 3 different ARV regimens, there is still a concern about the toxic 
effects of ARV therapy on endothelial cells (Table 3). 
Table 3: Effects of ARVs on endothelial cell homeostasis:
40
 
Drug class Drug Name Abbreviation Effect on 
endothelium 
NRTIs Zidovudine AZT, ZDV ↓ vasorelaxation 
 Stavudine d4T ↑ ROS 
 Didanosine ddI ↑ vasoconstrictor 
release 
 Zalcitabine ddC ↑ proliferation 
 Abacavir ABC ↑ permeability 
 Emtricitabine FTC ↓ mitochondrial 
function 
 Lamivudine 3TC ↓ GSH 
 Tenofovir TDF Not documented 
NNRTIs Nevirapine NVP Not documented 
 Efavirenz EFV Not documented 
 Delavirdine DLV Not documented 
PIs Ritonavir RTV ↑ carotid IMT 
 Atazanavir ATV ↓ FMD 
 Amprenavir APV ↔ IMT 
 Indinavir IDV ↔ FMD 
 Nelfinavir NFV ↓ mitochondrial 
function 
 Darunavir DRV ↑ ROS 
 Saquinavir SQV ↑ mtDNA damage 
 Fosamprenavir FPV ↑ permeability 
 Tipranavir TPV ↓ vasorelaxation 
 Lopinavir LPV ↓ eNOS 
Integrase Inhibitor Raltegravir RAL Not documented 
EIs Enfuvirtide ENF Not documented 
 Maraviroc MVC Not documented 
↑: increase; ↓: decrease; ↔: no change; GSH: glutathione; HDLc: high-density 
lipoprotein cholesterol; ROS: reactive oxygen species; IMT: intima media 
thickness; FMD: flow-mediated dilation; eNOS: endothelial nitric oxide synthase; 
mtDNA: mitochondrial DNA. 
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Glucose intolerance and dyslipidemia have been documented to occur in patients 
treated with protease inhibitors (PIs). A 16% increased risk of myocardial 
infarction for each year of exposure to PIs has also been documented.
68
 Previous 
reports have linked the use of PI containing ARV regimens to a hypercoagulable 
state. In a study by Koppel et al.
69
 plasminogen activator inhibitor 1 (PAI-1) and 
fibrinogen levels were found to be significantly higher in patients receiving PI-
containing ARV regimens. In addition, the increased plasma lipid levels and the 
lipodystrophy syndrome could play a procoagulant role. In a review article in 
2004, Shen et al.
70
 came to the conclusion that, based on epidemiological studies, 
a hypercoagulable state and associated venous thromboses were emerging as 
clinical issues in HIV infected patients with the use of PIs being particularly 
implicated.  
 
The effects of the different classes of ARVs on endothelial function have also 
been studied and the results are summarised in Table 3. Clinical evidence for 
NRTI-induced vascular / endothelial toxicity is indirect and difficult to define 
because NRTIs are not prescribed as monotherapy. In addition, most 
experimental in vitro studies examining mitochondrial toxicity of NRTIs are 
conducted in liver cell lines due to their endogenous abundant mitochondria, the 
liver's involvement in NRTI metabolism and the documented hepatic dysfunction 
encountered in patients on NRTI treatment. Although in vitro studies linking 
NRTIs to endothelial cell-specific toxicity are therefore not as numerous, 
evidence does support a role for NRTIs in endothelial dysfunction. Aortas from 
mice treated with AZT, have been demonstrated to have reduced maximum 
endothelium-dependent relaxation. Future investigation into the multiple direct 
and indirect effects of NRTIs on mitochondrial gene expression
 
and reactive 
oxygen species generation are indicated to accurately determine how this 
important class of drugs exerts its toxic effects on the endothelium.
40
  
 
In contrast to the NRTIs, there are even fewer in vitro studies examining 
endothelial toxicity in response to NNRTI treatment. In fact, clinical studies on 
the cardiovascular effects of NNRTIs have demonstrated overall atherosclerotic 
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protective effect when switching to a NNRTI-based ARV regimen. This positive 
result relates to the improved lipid profiles and reduced blood pressure on NNRTI 
treatment.
40
 
  
Controversy exists regarding PI-based therapy and cardiovascular risk. 
Discrepant results have been obtained when studying the correlation between PI 
exposure and endothelial dysfunction as evidenced by increased intima media 
thickness (IMT) of the carotid bifurcation and decreased flow mediated dilatation 
(FMD) of the brachial artery. Various explanations exist for these discrepant 
findings but despite these contradicting reports, long-term treatment with PIs has 
generally been associated with a number of cardiovascular side effects including 
a greater incidence of diabetes mellitus, lipodystrophy, hyperlipidemia and 
atherosclerosis with an increased risk of myocardial infarction. The molecular 
mechanisms of PI toxicity in endothelial cells probably involve mitochondrial 
disturbances as evidenced by reduced cellular respiration and ATP production, 
decreased mitochondrial membrane potential, increased mitochondrial production 
of ROS, altered nitric oxide (NO) metabolism and mitochondrial DNA damage.  
PIs also increase endothelial cell permeability and leukocyte adhesion in cell 
culture models. PI effects on non-endothelial cells may also contribute to 
cardiovascular risk. For example, PIs dysregulate fat cell homeostasis which may 
explain the high incidence of lipodystrophy and hyperlipidemia in HIV patients 
receiving PI based ARV regimens. Besides adipocytes, macrophages are also 
extra-endothelial targets of PI toxicity. PIs, most notably ritonavir, cause 
accumulation of cholesterol in macrophages by activating the unfolded protein 
response and by up-regulating the scavenger receptor CD36.
 
PIs also increase 
expression of the pro-inflammatory cytokines TNF-α and IL-6. Thus, PI-mediated 
changes in gene expression, activation of cell signalling pathways and oxidative 
stress in endothelial and non-endothelial cells can negatively impact 
cardiovascular health.
40
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1.11 Conclusion 
Given all the above evidence of the presence of a hypercoagulable state in HIV 
infection, Klein SK et al. 
2
 reviewed the evidence of a link between HIV 
infections and venous thrombotic disease. The authors of this systematic review 
found that there is limited evidence coupling these two conditions. Ten relevant 
epidemiological studies of venous thrombotic disease in HIV infections were 
identified. These studies were however retrospective cohort studies prone to 
selection bias with confounding variables not always mentioned and only three of 
the ten studies included a control group. Their conclusion was that although some 
evidence pointed towards a relationship between HIV infection and venous 
thrombotic disease, more studies were indicated to further elucidate this link.  
 
Lijfering WM et al.
11
 investigated 109 consecutive HIV-infected patients with a 
median follow-up period of 5 years and reconfirmed the presence of the 
prothrombotic factors discussed above with worsening of these parameters as 
HIV infection progressed to AIDS. Cytokines may play an important role in the 
worsening prothrombotic state as HIV progresses since the same cytokines which 
activate the coagulation system have been described to increase in concentration 
as HIV infection progresses. In addition, a clearly increased incidence of both 
venous and arterial thromboses was demonstrated as compared to the incidence in 
an HIV negative cohort. The annual incidence of venous (1.61%) and arterial 
thrombosis (0.87%) were 5- to 16-fold and 2- to 8-fold higher respectively 
compared with a healthy HIV uninfected cohort (i.e. 0.1% – 0.3% and 0.1% - 
0.4%). The median age at onset of venous and arterial thromboses was also 
earlier in the HIV positive cohort.  This study concluded that the results do 
suggest that HIV infected patients are at higher risk of thromboses but that further 
research was needed. 
 
The vast majority of the studies reporting on the documented prothrombotic 
abnormalities in HIV infection as summarised in Table 4 were conducted in first 
world cohorts. Differences in HIV infection and its consequences between the 
first and third world do exist and is discussed further in section 5.1.   
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Table 4: Comparison of the prevalence of prothrombotic risk factors 
between HIV infected and uninfected individuals:
11, 71
 
Category of 
prothrombotic 
abnormality 
Specific 
abnormality 
Reported 
frequency of 
congenital / 
acquired 
deficiency in 
the general  
population 
Reported 
frequency in 
HIV positive  
population 
Deficiency of 
anticoagulants 
Protein S 
deficiency 
Congenital: 
<0.5% 
 
20 – 80% 
 Protein C 
deficiency 
Congenital: 
0.2 – 0.4% 
(1.5% 1
st
 
VTEs) 
 
14% 
 Antithrombin 
deficiency 
Congenital: 
0.2% 
 
?? 
 Heparin cofactor II 
deficiency 
 
?? 
 
?? 
Presence of 
specific 
prothrombotics 
Antiphospholipid 
antibodies 
 
1-5% 
 
70-90% 
 Increased FVIII Congenital: 
10% 
41% 
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2. Study objective 
 The objective of this cross-sectional study was to determine the prevalence of underlying 
HIV infection in patients presenting with acute deep vein thrombosis (DVT) without the 
presence of traditional risk factors for DVT. Presence of DVT risk factors including 
underlying cancer, prolonged bed rest (>4 days), pregnancy, infections (particularly 
tuberculosis), recent (within last month) surgery / trauma, advanced age (>65 years) and 
long distance travel (> 8 hrs) were sought. DVT risk factor determination was based on 
clinical patient assessment including history and examination. No laboratory testing for 
thrombophilia was performed.  
 
 The HIV prevalence in the cohort of patients with acute DVTs was compared to the HIV 
prevalence in a sex, age and race matched control group without symptomatic DVT.  
 
 This was a pilot study with an anticipated prevalence of 80% from observations made in 
the past. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38 
 
3. Study populations, materials and methods 
3.1 Case selection 
Consecutive male and female adult patients presenting to the Charlotte Maxeke hospital 
casualty with lower limb acute deep vein thrombosis (DVT) confirmed on venous 
Doppler ultrasound were invited to participate in this cross sectional study. Eligibility 
criteria were as follow: 
 Community integrated members of the society i.e. out of hospital patients 
presenting with acute DVTs  
 Adult patients over the age of 18yrs  
 Male and female patients  
 
Voluntary HIV testing of the participants were performed after counselling and consent 
with appropriate referral for further management if HIV result was positive. 
The presence of commonly encountered traditional risk factors for the development of 
DVTs i.e. underlying cancer, prolonged bed rest (>4 days), pregnancy, infections 
(particularly tuberculosis), recent (within last month) surgery / trauma, advanced age 
(>65 years) and long distance travel (> 8 hrs) was ascertained on patient history and 
examination.  
 
3.2 Control selection 
The control group was an age, sex and race matched cohort consisting of laboratory 
personnel not subordinate to the investigator. The prevalence of HIV infection in this 
matched population without symptomatic DVTs was determined. Exclusion of DVTs in 
the control population was based on the absence of classic DVT signs such as unilateral 
swelling, pain and redness of a limb.   
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3.3 Statistical analysis 
The University of the Witwatersrand Epidemiology Data Centre assisted with analysis of 
the data.  
3.3.1 Sample Size: 
A sample size of 25 subjects with acute DVTs was deemed adequate by Professor 
P Becker of the Department of statistics of the Medical Research Council (MRC) 
to estimate the expected HIV prevalence of 80% to an accuracy within 15% of the 
95% confidence level. 
A sample size of 24 control subjects without DVTs was deemed adequate to 
estimate the expected HIV prevalence in the control group in this pilot study and 
to guide future research in this field.  
 
3.3.2 Data analysis: 
The prevalence of HIV is expressed as a percentage along with a 95% confidence 
interval (CI). 
 
3.3.3 Calculation of prevalence: 
Prevalence is a measure of how commonly a disease or condition occurs in a 
population at a particular point in time. The prevalence was calculated by 
dividing the number of subjects with the disease / condition at a particular time 
point by the total number of individuals examined. Prevalence was expressed as a 
percentage, calculated by multiplying the ratio by 100. 
 
3. 4 Ethics 
Ethics approval was obtained from the Human Research Committee of the faculty 
of Health Sciences, University of the Witwatersrand (protocol number M051029) 
and approval was unconditional. Both patients and controls were invited to 
participate in the study and verbal informed consent was obtained from both 
groups. The study was conducted over a 24 month period between 2005 and 
2007. 
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4. Results 
 
The demographics and clinical details of the patients presenting with acute DVTs are 
detailed in Table 5 and 6. Table 7 reflects the details of the control cohort i.e. a matched 
population without clinical evidence of DVTs. 
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 Table 5: Demographics and clinical details of DVT patients (arranged per age): 
 
No: Sex 
Age 
(yrs) Race 
HIV  
Status 
CD4  
(x10
6
/L) 
Position 
of DVT 
Traditional DVT 
 risk factors 
1 F 22 Black + ND AK DVT  
2 F 23  Black +  
 
 
190 AK DVT  
3 F 25 Black + 23 AK DVT PTB on Rx / immobile 
4 M 26  Black + 199 AK DVT PTB not on Rx 
5 M 27  Black + 74 AK DVT  
6 F 27 Black - ND AK DVT PTB on Rx 
7 F 28 Black + 197 AK DVT PTB on Rx / immobile 
8 F 28 Black + 800 AK DVT  
9 M 29 Black ND ND AK DVT PTB not on Rx 
10 F 30  Black + 98 AK DVT  
11 M 31  Black + 339 AK DVT  
12 F 33 Black + 52 AK DVT  
13 M 33 Black + 105 AK DVT PTB not on Rx 
14 F 35 Black + 582 AK DVT  
15 M 37 Black + 272 Popliteal 
DVT 
 
16 F 37 Indian ND ND AK DVT SLE arthritis / immobile 
17 F 38 Black + 225 AK DVT  
18 F 39 Black + 178 AK DVT  
19 M 39 Black + 151 AK DVT  
20 F 40 Black + 264 AK DVT  
21 F 40 Black + 21 AK DVT  
22 F 40 Black + 378 AK DVT  
23 M 42 Black ND ND AK DVT  
24 F 44 Black + 172 AK DVT  
25 M 45 Black + 451 AK DVT  
26 F 45 Black + 155 AK DVT  
27 M 45 Black + 810 AK DVT  
28 M 47 Black + 43 AK DVT  
29 F 47 Black + 170 AK DVT Carcinoma of cervix                                             
0   000 30 M 50 Black - ND AK DVT Fractured ankle / 
immobilisation  31 F 51 Black + 273 AK DVT                                                  
32 F 52 White ND ND AK DVT  
33 F 52 White - ND Bilateral 
AK 
DVTS 
 
34 M 53 Black - ND Bilateral 
AK 
DVTs 
 
35 M 56 Black + 136 Popliteal 
DVT 
 
36 F 57 Black 
 
 
ND ND AK DVT Ca cervix / immobile  
cercervix;iimmobilw 37 M 59 White - ND AK DVT  
38 M 64 White ND ND Popliteal 
DVT 
Previous DVT 
39 M 65 Coloured ND ND AK DVT Age >  65 yrs 
40 F 66 White ND ND AK DVT Age >  65 yrs 
41 M 68 White ND ND AK DVT Age >  65 yrs 
42 F 68 Black ND ND AK DVT Age >  65 yrs 
43 F 69 White ND ND Popliteal 
DVT 
Ca vulva />65/immobile 
65yrs/immobile 
yrsimmobilisedimmobil
isation iimmobilisation 
immobilised 
44 F 72 Black ND ND AK DVT Age >  65 yrs 
45 F 74 White ND ND Popliteal 
DVT 
Injury/> 
65/immobile 
y6565/immobile 
46 F 76 White ND ND AK DVT Age >  65 yrs 
47 F 78 Black ND ND AK DVT Age >  65 yrs 
48 M 79 Black ND ND AK DVT Age >  65 yrs / 
immobile F: Female; M: Male; +: positive; -: negative; ND: Not done; AK: Above knee;  
PTB: pulmonary tuberculosis; SLE: systemic lupus erythematosus; 0: No risk factor identified  
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Table 6: Demographics and clinical details of DVT patients without traditional  
risk factors for DVT and who consented to HIV testing: 
 
No: Sex 
Age 
(yrs) Race 
HIV  
Status 
CD4  
(x10
6
/L) 
Position 
of DVT 
1 F 22 Black + ND AK DVT 
2 F 23  Black +  
 
 
190 AK DVT 
3 M 27  Black + 74 AK DVT 
4 F 28 Black + 800 AK DVT 
5 F 30  Black + 98 AK DVT 
6 M 31  Black + 339 AK DVT 
7 F 33 Black + 52 AK DVT 
8 F 35 Black + 582 AK DVT 
9 M 37 Black + 272 Popliteal 
DVT 
10 F 38 Black + 225 AK DVT 
11 F 39 Black + 178 AK DVT 
12 M 39 Black + 151 AK DVT 
13 F 40 Black + 264 AK DVT 
14 F 40 Black + 21 AK DVT 
15 F 40 Black + 378 AK DVT 
16 F 44 Black + 172 AK DVT 
17 M 45 Black + 451 AK DVT 
18 F 45 Black + 155 AK DVT 
19 M 45 Black + 810 AK DVT 
20 M 47 Black + 43 AK DVT 
21 F 51 Black + 273 AK DVT 
22 F 52 White - ND Bilateral 
AK 
DVTS 
23 M 53 Black - ND Bilateral 
AK 
DVTs 
24 M 56 Black + 136 Popliteal 
DVT 
25 M 59 White - ND AK DVT 
F: Female; M: Male; +: positive; -: negative; ND: Not one AK: Above knee 
 
A total of 48 consecutive community integrated out-patients presenting to the Charlotte 
Maxeke hospital medical casualty with acute lower limb DVTs were enrolled in the 
study (Table 5).  
 
The HIV prevalence in the deep vein thrombosis (DVT) group who consented to HIV 
testing i.e. 25 patients and who had no traditional risk factor for DVT development was 
81% (95% CI 0.67 - 0.96) (Table 6). All the DVT patients who consented to HIV testing 
were active, community integrated members of the society. 
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The average CD4 cell count of the HIV positive patients with acute DVTs was 247 /mm
3
 
with a range of 21 to 810. 
 
Two of the HIV positive patients presenting with DVTs were on ART (anti-retroviral 
therapy) at the time of developing a DVT. 
 
Six of the patients presenting with acute DVTs were also diagnosed as suffering from 
pulmonary tuberculosis with 3 patients receiving anti-tuberculosis therapy at the time of 
presentation. HIV testing was done on 5 of the 6 patients and 4 of them tested HIV 
positive. The average CD4 count of these 4 patients was 131/mm
3
.  
 
Traditional DVT risk factors identified in the acute DVT cohort other than tuberculosis 
were immobilisation (1 patient), trauma (2 patients), carcinoma (2 patients), previous 
DVT (1 patient) and age over 65 years (10 patients).  
 
In a matched control group the HIV prevalence was found to be 4% (95% CI 0.039 – 
0.041).  The control group consisted of healthy, active adults without symptoms or signs 
suggestive of DVT (Table 7): 
 
 
 
 
 
 
 
 
 44 
 
Table 7: Demographics of control cohort (arranged according to age): 
 
Number Sex Age (yrs) Race HIV result 
1 M 20 Black - 
2 F 21 Black - 
3 M 21 Black - 
4 F 22 Black - 
5 M 23 Black - 
6 F 23 Black - 
7 F 24 Black + 
8 M 26 Coloured - 
9 F 28 Black - 
10 M 32 White - 
11 M 32 Black - 
12 F 33 Black - 
13 M 34 Black - 
14 M 36 Black - 
15 F 36 Coloured - 
16 F 36 Black - 
17 F 37 Black - 
18 M 38 White - 
19 M 42 Black - 
20 F 46 Black - 
21 F 48 Black - 
22 F 52 White - 
23 F 58 White - 
24 F 60 Black - 
F: Female; M: Male; +: positive; -: negative. 
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Table 8: Comparison of demographics of DVT patients without traditional risk 
factors and control cohort: 
Demographic parameter DVT patients (consented to 
HIV testing and no 
traditional DVT risk 
factors) 
Control cohort (No 
symptoms of DVTs)  
Number of subjects 25 24 
Average Age (Age range) 39 (22 – 59) 36 (20 – 60) 
Sex Females: 15 
Males: 10 
Females: 14 
Males: 10 
Race Black: 23 (92%) 
White: 2 (8%) 
Coloured: 0 
Black: 19 (79%) 
White: 3 (12.6%) 
Coloured: 2 (8.3%) 
  
The prevalence of HIV infection in the population with DVTs who consented to HIV 
testing of 81% (95% CI 0.67 - 0.96) was therefore significantly higher than that in the 
control group with a HIV prevalence of 4% (95% CI 0.039 – 0.041). 
 
According to the South African National HIV Prevalence, HIV Incidence, Behaviour and 
Communication Survey commissioned by the Nelson Mandela Foundation in 2005, the 
estimated prevalence of HIV infection in the general South African population above the 
age of 2 years was 10%. Again the HIV prevalence in the DVT patient cohort was 
significantly higher than that in the general population i.e. 81% vs. 10%. Although the 
DVT patient group was not completely representative of the general South African 
population as far as age was concerned, other demographics were similar and the 
prevalence of HIV infection in these 2 groups can also be compared. 
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5. Discussion 
5.1 Worldwide differences in the HIV epidemic 
The HIV epidemics in the first and the third world differ in the prevalence of HIV 
subtypes. There also are documented differences in host susceptibility, co-
morbidities and disease manifestations between race and socio-economic groups. 
Published studies on the prevalence, underlying cause and prognosis of DVTs in 
HIV infection have largely been performed in the first world in mainly Caucasian 
populations.
7, 72
 
In this study, twenty two (22) of the twenty five (25) DVT patients with no 
traditional DVT risk factors and who consented to HIV testing were found to be 
HIV positive. All these patients were of African descent. 
As mentioned above, published studies on the prevalence, underlying cause and 
prognosis of DVTs in HIV infection have largely been performed in the first 
world in Caucasian populations and further research is needed in sub-Saharan 
Africa. The current study therefore is a pilot study to direct future studies in this 
regard. 
 
5.2 The HIV prothrombotic state and role of ARVs 
5.2.1 Documented prothrombotic abnormalities in HIV infection 
Section 1 of this dissertation details the various abnormalities predisposing to a 
hypercoagulable state in patients with HIV infection. In summary, these include 
deficiencies in anticoagulant factors such as protein S and C, antithrombin and 
Heparin-cofactor II as well as an increase in or presence of procoagulant factors 
such as antiphospholipid antibodies (Lupus Anticoagulant and anticardiolipin 
antibodies) and FVIII / vWF (Table 4). Endothelial cell activation and presence 
of microparticles may also contribute. Concurrent malignancies and secondary 
infections worsen the procoagulant profile as would the presence of  traditional 
DVT risk factors such as immobilisation, pregnancy advanced age and long 
distance travel.
3
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5.2.2 Prothrombotic profile with HIV disease progression 
The average CD4 cell count of the HIV positive patients with acute DVTs who 
consented to HIV testing in this study was 247 x 10
6
 cells per liter. The average 
CD4 count in this cohort was therefore slightly higher than that reported in the 
literature in HIV patients presenting with thromboses. Klein et al.
2
 in their review 
in 2005 for example demonstrated the risk of DVT to be increased in HIV 
positive patients with AIDS or with CD4 counts below 200 x10
6 
per liter. 
 
Progression of HIV infection occurs along a wide spectrum. At the extremes of 
this spectrum some patients rapidly progress to clinical disease, while others 
behave as the poorly understood long-term non-progressors. In between these two 
poles, lies the majority of the infected population.
73-74
 Anti-retroviral therapy 
(ART), where freely available, has significantly transformed infection with HIV 
from a terminal, life-threatening illness to a chronic manageable disease. The 
natural history of treated HIV infection and the long-term efficacy of 
antiretroviral agents remain however unknown. The entire spectrum of short and 
long-term ART-related side effects also needs to be elucidated. 
 
Various studies
3, 11, 24, 75-77
 have documented worsening coagulation profiles with 
progression of HIV infection. Median factor VIII concentrations were found to be 
higher in patients with AIDS (CD4 cell counts < 200 x 10
6
 per liter) than in 
patients with a non–AIDS-defining illness. Median free protein S concentrations 
were lower in the first group. These changes correlated with increasing fibrinogen 
concentrations.
11
 The worsening laboratory parameters translated into higher risks 
of thrombosis in HIV positive patients with AIDS versus infected patients 
without AIDS defining disease processes.
19, 78-79
  
 
The aetiological link between HIV disease progression and the worsening 
prothrombotic state is largely unknown but a link between infection and 
thrombosis via endothelial activation has been suggested. Changes in the cytokine 
profile coupled with increases in acute phase reactants and opportunistic 
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infections probably also play a role.
35, 80
 The same cytokines responsible for 
endothelial activation are also incrementally up-regulated during the course of 
HIV infection.
15, 81
  The pro-inflammatory cytokines implicated in this process 
include tumor necrosis factor-, interleukin-1 and interleukin-6. Not only do they 
have an effect on the inflammatory process but they also activate coagulation and 
down-regulate the production of fibrinolytic proteins.
82-83
  
 
As HIV infection progresses, there is a concomitant progression of laboratory 
abnormalities consisting of increased concentrations of procoagulant proteins and 
decreased concentrations of anticoagulant proteins. This increasing procoagulant 
profile results in an increased incidence of venous and arterial thrombosis.
11,
 
84-88
 
 
The procoagulant proteins which have been implicated are FVIII and fibrinogen 
and they are both acute phase reactants.
84-85, 87
 As far as deficiencies of 
anticoagulants are concerned, low concentrations of protein C have been reported 
in various infections including HIV infection. Decreased protein C levels during 
infection possibly related consumption during its action as an anti-inflammatory 
mediator. Although inherited protein C deficiency has been demonstrated to be a 
strong risk factor for venous thrombosis, the risk associated with acquired protein 
C deficiency has not been as well documented. Nonetheless, protein C deficiency 
also worsens with HIV disease progression.
89
  
 
Normally 60% of protein S is bound to C4BP and it is only the remaining 
approximately 40% of this anticoagulant protein which is physiologically 
optimally active as an anti-coagulant.
90
 During active infection, the concentration 
of C4BP increases to up to 400% of its normal baseline concentration. Various 
studies have documented concentrations of protein S to be decreased in HIV-
infected patients with the levels worsening as HIV infection advances.
13-14, 24, 91
  
In conclusion, there are multiple acquired and usually persistent thrombophilic 
abnormalities present in HIV-infected patients. The frequency and severity of 
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these thrombophilic abnormalities increase with the progression to AIDS and 
probably contribute to the high prevalence of venous and arterial thrombosis in 
HIV-infected patients, especially in advanced disease.
11, 24
 
    
5.2.3  Antiretroviral drugs (ARVs) as prothrombotic factors 
Only 6 of the 26 HIV infected patients presenting with DVTs in the current 
cohort were receiving ARVs at the time of presenting with a DVT. This figure 
represents 23% of the DVT cohort that tested positive for HIV and 42% of the 
patients eligible for ARVs i.e. patients with CD4 counts below 200 x10
6 
per liter. 
These figures probably reflect the inaccessibility of ARVs in South Africa. 
Inadequate public awareness as well as a lack of participation in HIV voluntary 
counselling and testing programmes probably also contribute.  
 
Although the benefits of ARV therapy are beyond dispute, further exploration 
into the precise mechanisms of ARV drug toxicity is warranted. Since both the 
hypercoagulable state and endothelial dysfunction in HIV infected individuals are 
most likely multifactorial processes, the exact contributions by the viral infection 
itself and the drugs used to treat it, are needed. 
 
5.3 The TB prothrombotic state 
In the current cohort of 48 patients presenting with acute DVTs, 3 patients were 
on treatment for pulmonary TB at the time of presenting with a DVT. An 
additional 3 of the DVT cohort were subsequently diagnosed with pulmonary TB. 
Four of the 6 patients with tuberculosis tested positive for infection with HIV. 
 
In a retrospective analysis in a South African hospital in the mid 1980s, White et 
al.
92
 found DVTs in 3.4% of TB patients within the first two weeks after initiation 
of anti-tuberculosis therapy. The prevalence rate of DVTs occurring in patients 
receiving rifampicin as part of their ant-TB treatment regimen was increased by 
approximately 5%.   
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TB can cause thrombosis by various mechanisms such as local vascular invasion, 
venous compression by enlarged lymph nodes or by producing a transitory 
hypercoagulable state. Robson et al.
93
  suggested that elevated plasma fibrinogen 
and factor VIII, impaired fibrinolysis coupled with decreased levels of 
antithrombin and reactive thrombocytosis appeared to favour the development of 
DVT in pulmonary TB. There is also data supporting a relationship between the 
prothrombotic state in TB infections and a presence of antiphospholipid 
antibodies and protein S deficiency present during this infection. The protein S 
deficiency is secondary to decreased liver production and increased levels of C4-
BP reducing the free fraction of protein S.  
 
Vascular endothelium may be primed to become prothrombotic by mycobacterial 
products. The host monocyte–macrophage system is induced to synthesise large 
amounts of cytokines including tumour necrosis factor alpha (TNFα) and 
interleukin-6. Cytokine production further increases during bacterial death related 
to anti-tuberculosis therapy. These cytokines block the protein C anticoagulant 
pathway and induce tissue factor (TF) production on endothelium and monocytes. 
Interleukin 6 also stimulates new platelet formation with these platelets 
displaying increased sensitivity to thrombin activation and increased pro-
coagulant activity.
49
 
 
The resultant procoagulant state during TB infection improves during the first 
month of therapy and therefore prophylactic anticoagulation therapy should 
always be considered at initiation of anti-tuberculosis therapy and for the first 3-4 
weeks thereafter. Dose adjustment of anticoagulant drugs may also be necessary 
to achieve therapeutic and prophylactic anticoagulation levels because of the 
induction of the drug metabolising enzyme, cytochrome P450, by rifampicin, a 
cornerstone anti-tuberculosis drug. In addition, this drug may also contribute to 
the hypercoagulable state by decreasing production and increasing clearance of 
anticoagulant proteins i.e. antithrombin, protein S and C.
94
 Patients receiving anti-
tuberculosis therapy require frequent INR monitoring and increased warfarin 
doses are often needed to maintain a therapeutic warfarin effect. Abruptly 
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stopping rifampicin could be potentially hazardous resulting in over 
anticoagulation. Full induction of drug-metabolising enzymes is reached about 1 
week after starting rifampicin and the induction dissipates roughly 2 weeks after 
discontinuing this anti-tuberculosis drug.
49
 
 
In conclusion, an association between the inflammation induced by TB and a 
hypercoagulable state has been described. Therefore, the occurrence of DVT or 
pulmonary embolism should be considered in patients with TB and suggestive 
symptoms especially during the first weeks of treatment. Early diagnostic 
suspicion of VTE is important to ensure appropriate diagnosis and prompt 
treatment in order to prevent fatal outcomes. A high index of suspicion is needed 
in patients that are thought to be responding poorly to anti-tuberculosis treatment 
and have other predisposing factors, such as concomitant HIV infection. Patients 
who need prolonged in-hospital admission should be carefully monitored and the 
use of prophylactic anticoagulation should be considered. 
 
5.4 HIV voluntary counselling and testing (VCT) 
In the DVT cohort reported on here, 16% of patients under the age of 65 years 
refused HIV testing after counselling. A similar proportion of eligible people 
without DVTs approached to participate in the control arm of the study refused to 
participate when informed that VCT for HIV would be required.  
 
Various studies
95-97
 have investigated participation in VCT programmes. These 
studies concluded that the fear of receiving HIV-positive results make individuals 
postpone testing, resulting in inappropriate delays in seeking treatment. This has 
resulted in patients presenting in advanced disease stages. 
 
Uganda is one of the countries in Africa with relative success in the HIV/ AIDS 
prevention arena. The HIV/AIDS epidemic in Uganda developed silently and 
took advantage of the war ravaged healthcare services leaving over 50% of the 
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population without primary healthcare in the early 1980s.  The HIV prevalence 
increased to an estimated 15% in the mid 1990’s. With VCT and a campaign 
termed ABC (Abstinence, Be faithful and Condomise) the trend turned sharply 
downward to 5% in the 2003. Stigma however remains an important role player 
even in a country such as Uganda where roughly half the people surveyed in 2005 
indicated that if a family member contracted HIV they would prefer to keep it 
secret.
98
 Stigmatisation suffered by people living with HIV/AIDS can arise from 
the patient themselves, from the family and can also have its origin in the larger 
community with men viewed as the traditional breadwinners having their 
positions in society most threatened. Recent studies show transport fares, denial 
of  HIV-positive results and marital dissolution to be additional barriers to 
VCT.
99-100
 
   
Living with HIV/AIDS carries not only stigma but also the emotional strain of 
being unable to provide and care for dependents and fear of pain and suffering. 
Nyanzi-Wakholi et al.
98
 reported that many women indicated the desire to end 
intimate sexual relationships on testing HIV-positive whilst men in similar 
situations indicated the need to affirm their relationships so as to have a caretaker. 
 
While the role of VCT in curbing the HIV/AIDS epidemic remains debatable, 
research has demonstrated that VCT not only informs individuals of their HIV 
sero-status but personalises the risk of infection and encourages treatment 
seeking.
99-101
   
 
Nyanzi-Wakholi et al.
98
 reported that men were especially reluctant to undergo 
VCT and preferred to postpone VCT until they were evidently sick. They 
acknowledged preferring to live in doubt of their status rather than living with the 
certainty of being HIV infected. Most women reported deciding to undergo VCT 
after they or their partners and / or children developed HIV/AIDS-related 
illnesses. Individuals in their study expressed fear that they will commit suicides 
if they were to discover that they were HIV positive. Access to free care from 
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HIV/AIDS support organisations for patients with a positive result did however 
serve as an incentive to undergo testing. Various studies
102-104
 emphasise the 
crucial role of pre-and post-test counselling and informed support groups in 
enabling people testing HIV-positive to understand and accept their status, adhere 
to treatment regimens and live positively.  
 
5.5 Anticoagulation in the HIV infected patient 
VTE prophylaxis with both low molecular weight heparin (LMWH) and 
unfractionated heparin (UFH) have been proven to be safe and effective in 
medical in-patients at risk of VTE.
61-62, 105-106
 LMWH has several important 
advantages over UFH when used for thromboprophylaxis including less adverse 
side-effects like major bleeding and heparin-induced thrombocytopenia.
107-109
 It 
also offers more convenience with once-daily dosing in pre-filled syringes. It is 
however more costly. 
 
These advantages are even more important in the HIV positive patients who often 
present with thrombocytopenia relating to HIV induced autoimmune peripheral 
platelet destruction. In addition, once daily administration of LMWH decreases 
the exposure of nursing staff to contaminated needles. Although LMWH costs 
more per dose, the total hospital cost has been shown to be lower and may be 
related to fewer major bleeding episodes occurring in patients receiving LMWH 
as opposed to UFH.
110
  
 
5.6 Traditional risk factors for DVT development 
This dissertation aims to explore the prevalence of HIV infection in newly 
diagnosed DVT patients without any of the traditional risk factors for the 
development of DVT. However traditional risk factors for DVT development 
were present in both DVT patients who tested positive and negative for HIV 
infection and in those refusing HIV testing. The pathophysiologic mechanisms 
involved in the most common traditional risk factors for DVT development are 
therefore discussed.  
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5.6.1 Underlying malignancy 
One of the HIV positive patients in this cohort presenting with a DVT was on 
treatment for cervical cancer, which is considered to be an AIDS defining illness. 
One patient in the cohort with acute DVT had underlying carcinoma of the cervix 
and another of the vulva but the HIV status of both these patients was not 
determined. The extent to which the patients in this cohort presenting with DVTs 
were investigated to exclude underlying malignancy is also not known.  
 
Neoplastic diseases clearly seen with an increased frequency in patients with HIV 
infection are Kaposi sarcoma and non-Hodgkin’s lymphoma, the latter also being 
and AIDS defining illness. Cervical carcinoma is also an AIDS defining disease 
process. In addition, there also appears to be an increased incidence of Hodgkin’s 
disease, multiple myeloma, leukaemia, melanoma and oral, lung and anal 
carcinoma in HIV infected ptaients.
67
 
 
It is therefore clear that the mechanisms underlying cancer thrombosis share 
many similarities with the HIV thrombotic state and therefore co-existence of 
these disease processes poses a significant thrombosis risk. Appropriate and safe 
use of anticoagulation therapy, whether therapeutic or prophylactic, in the HIV 
positive cancer patient can be complicated by the presence of thrombocytopenia 
which is frequently present in HIV patients. Thrombocytopenia can also be 
worsened by certain malignant processes and chemotherapy. The conclusion of a 
recent study involving 1 514 in-patients post bone marrow transplantation 
demonstrating that  DVTs occurred with regular frequency in patients with 
platelet counts below 50 x 10
9 
per liter.
54
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5.6.2 Immobilisation / Bed rest 
In the current cohort of patients with acute DVTs described here, 8 of the 48 
patients (16%) admitted to significant bed rest immediately prior to their 
presentation. All these patients also suffered from other DVT risk factors 
including tuberculosis, arthritis, carcinoma and age greater than 65 years. 
The current study aimed to explore the causal relationship between HIV infection 
and DVTs and therefore the presence of confounding factors such as prolonged 
bed rest was explored. A history of bed rest was present in 8 of the total cohort of 
patients presenting with acute DVTs and 3 of these patients also had underlying 
HIV infection. The reason for bed rest included musculoskeletal injuries, 
carcinoma and tuberculosis. The remainder of the patients with DVTs and 
documented HIV infection i.e. 22 patients, were community integrated active 
members of society at the time of developing a DVT and did not have significant 
histories of bed rest. 
 
5.6.3 Pregnancy 
All the female patients of reproductive age in this cohort of DVT patients 
underwent a pregnancy test and none were found to be pregnant.  
The concurrence of HIV infection and pregnancy can be expected to operate 
synergistically in creating a prothrombotic environment. 
 
5.6.4 Post surgery period 
None of the patients in the HIV positive DVT cohort had undergone surgery 
within the 6 months preceding development of a DVT. 
 
5.6.5 Advanced age 
The average age of the HIV positive patients presenting with a DVT was 44 years 
with the age range being 22 – 56 years. Therefore, although increasing age is a 
well known risk factor for the development of VTE, especially beyond the age of 
65 years, it was not a contributory DVT risk factor in the HIV positive cohort.  
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5.6.6 Long distance travel 
None of the patients in this DVT cohort were exposed to long distance travel of 4 
hours or more, within the month preceding the onset of DVT. 
 
Again it can be expected that underlying HIV infection and long distance travel 
will operate synergistically to create a hypercoagulable state. 
 
5.7 Venous thrombo-embolism (VTE) prophylaxis and treatment guidelines 
Although all the patients in the DVT cohort discussed in this dissertation were 
outpatients, many HIV infected individuals are admitted to hospital during the 
course of their diagnosis and management. 
 
Infection with HIV is not frequently recognised as an additive risk factor for VTE 
in both surgical and medical patients. A search of the Medline database found the 
South African version of these guidelines published in 2008
111
 to be the only one 
to list HIV infection as a risk factor for the development of VTE. This guideline 
classifies infection with HIV as imparting a high VTE risk. The 9 contains a 
sample of the guidelines reviewed. 
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Table 9: Thromboprophylaxis guidelines: HIV infection as a risk for VTE: 
Source Year 
published 
HIV included as a 
VTE risk factor 
American College of Chest 
Physicians (ACCP)
61,56
 
2008 No 
American Society of Clinical 
Oncology (ASCO) 
112
   
2007 No 
American Academy of Orthopaedic 
Surgeons (AAOS) 
113
 
2008 No 
National Institute of Clinical 
Excellence (NICE) (UK) 
114
 
2009 No 
Australian Government National 
Health and Medical Research 
Council (NHMRC) 
115
  
2003 No 
Southern Africa Society of 
Thrombosis and Haemostasis 
(SASTH) 
111
 
2009 Yes 
 
The absence of HIV in the list of VTE risk factors to be considered in medical in-
patients probably reflects the prevalence of HIV in these predominantly first 
world countries. 
 
Underlying HIV infection has also been excluded from studies attempting to 
elucidate effectiveness of thromboprophylaxis in medically ill patients. In a 
retrospective study titled “Thromboprophylaxis in medically ill patients at risk for 
venous thrombo-embolism” Burleigh et.al.116 included over 12 million patients 
from the Solucient’s ACTracker Inpatient Database between 2001 and 2004. All 
these patients had indications for thromboprophylaxis and rates of 
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thromboprophylaxis and mortality were compared between groups. The results 
demonstrated a significantly lower risk-adjusted mortality rate (p < 0.001) in the 
more than 2 million medical patients with indications for thromboprophylaxis 
who received the appropriate prophylaxis compared to those who did not. Patients 
with HIV infection were however excluded from the study. Unfortunately no 
reason was provided for this exclusion but it may have related to the frequent 
underlying haematological abnormalities detected in association with HIV 
infection as one of the other exclusions are given as “blood disorders”.  
 
5.8 Bilateral DVTs 
The prevalence of bilateral DVT in patients with single limb symptoms has been 
previously investigated and the results reported are variable but incidences 
reaching   32 % have been documented.
117-119
 
 
Casella et al.
120
 studied the prevalence of DVTs in 157 in-patients with clinical 
suspicion of DVT. Following duplex Doppler scanning, the presence of DVT was 
confirmed in 57 (36.3%) of the patients with 11 patients (19.3% of all DVTs) 
having bilateral thromboses. No isolated DVT contra-lateral to the symptomatic 
limb was observed. Risk factors for DVT development studied were age, sex, 
prolonged immobilisation, chronic venous occlusive disease, stroke, lower limb 
trauma, post operative state (up to 30 days), hormonal therapy, pregnancy and 
active HIV infection. In addition, the presence of cancer and thrombophilia were 
also recorded but no active search for these 2 risk factors was embarked upon by 
the study investigators. Active HIV infection and ileo-femoral thrombosis (i.e. 
proximal thromboses) were identified as risk factors for the development of 
bilateral DVTs. The association between active HIV disease and acute DVT of 
both limbs showed a relative risk of 3.9 (range of 1.5-10.17) for bilateral disease 
in comparison with non-HIV patients with DVT symptoms. The authors also 
recommended that patients with positive duplex findings of DVT extending to the 
common femoral veins in the symptomatic limb should undergo examination of 
the contra-lateral side. 
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Our study did however not confirm the findings of Casella et al.
120
. All the 
patients in the current cohort detailed in this dissertation underwent bilateral 
lower limb duplex Doppler examination with 2 of the patients having bilateral 
DVTs. Both of these patients consented to HIV testing and both tested negative 
for infection with HIV. Proximal DVTs i.e. ileo-femoral thromboses were present 
in both these patients.  
 
Doubt still remains as to the cost-benefit ratio of performing bilateral Doppler 
studies in suspected DVTs with studies concluding both in favour of and against 
bilateral scanning. Studies by Naidich
121
, Lohr
122
 and Prandoni
123
 for example 
concluded that the high prevalence of bilateral thromboses warrants bilateral 
scanning whereas other authors
124-128
 concluded that the adoption of routine 
bilateral scanning would increase costs without providing benefit or result in 
changed treatment.  
 
Casella et al.
120
 estimated the sensitivity and specificity of clinical examination in 
identifying bilateral thromboses to be 27.2% and 93.3% respectively with the 
positive and negative predictive values of clinical examination in identifying 
bilateral disease being 50.0 % and 84.3%, respectively. The authors concluded 
that clinical examination is not a reliable diagnostic method to diagnose bilateral 
DVT. 
 
As to the question whether or not documentation of the bilateral extent of a DVT 
offers benefit, it is important to realise that before the advent of Doppler 
scanning, phlebography (venography) was the investigation of choice. Bilateral 
investigation was thus rarely performed, because phlebography represented 
additional risks and costs. Although phlebography is still considered the gold-
standard diagnostic tool for lower limb DVT, especially for scientific studies, it 
has been almost abandoned in day to day clinical practice and replaced by duplex 
Doppler scanning. The latter diagnostic method offers lower cost, improved 
availability and virtual absence of complications. Actual described values of 
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accuracy are higher than 95% and allow effective evaluation of even 
infragenicular veins.
129-130
 The diagnosis of DVT in an asymptomatic contra-
lateral limb allows for early measures to avoid the development of symptomatic 
post thrombotic syndrome (PTS) with its social and economical burden. The costs 
of bilateral duplex scanning in patients with confirmed unilateral DVT may be 
largely offset by future savings. An unidentified contra-lateral thrombosis may 
lead to misinterpretation of future clinical manifestations, eventually causing 
confusion between chronic venous obstructions and acute thrombosis. If 
placement of an inferior vena caval filter is indicated, documentation of the 
bilateral extent of a DVT will prevent the puncturing and manipulation of guide 
wires and sheaths through a thrombosed vessel. 
 
In conclusion, an association between active HIV infection and the presence of 
bilateral DVTs has been demonstrated and various studies have argued the 
benefits of documenting the extent of thromboses. Further studies and 
recommendations in this regard are warranted in view of our findings which did 
not confirm these previous observations. 
 
6. Conclusion 
The HIV prevalence in the deep vein thrombosis (DVT) group who consented to HIV 
testing and who had no traditional risk factor for DVT development was 81% (95% CI 
0.67 - 0.96). This HIV prevalence was significantly higher than that in a matched 
population group without clinical DVTs with a HIV prevalence of 4%. 
 
Traditional risk factors for DVT development were identified both in the HIV positive 
and negative DVT groups. These factors included tuberculosis, immobilisation, trauma, 
cancer, previous DVT and age over 65 years. Presence of these factors in HIV infected 
patients probably adds to the hypercoagulable state. 
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From this thesis it is clear that there is no available evidence evaluating 
thromboprophylaxis specifically in HIV-infected individuals. The available thrombosis 
treatment guidelines lack recommendations in this growing sub-population. Important 
treatment decisions are therefore left to medical attendants without clear guidelines. HIV 
infection in the ARV era is a chronic disease with a clearly prothrombotic tendency. 
Future studies and guidelines should further define the thrombotic risk in the HIV 
infected population and direct treatment and prophylaxis. 
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